NEO100

Small molecule

Mechanism not established
—no market stage

Evidence outlook

Studies registered, no market-specific stage

Studies of this drug are registered, but none is matched to a market this site covers, so no stage is set and there is nothing to grade. The registry list shows each study.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Other / comorbidity
NCT05023018 · Neonc Technologies, Inc.
2022-07-01 – 2027-06-30 · Residual, Progressive or Recurrent Grade II or III Meningioma
What this study did
Phase 1 (1)
Other / comorbidity
NCT06357377 · Neonc Technologies, Inc.
2026-09-08 – 2027-07 · Pediatric Tumor of CNS, Pediatric Tumor of Brain, Diffuse Midline Glioma, H3 K27M-Mutant, Pediatric Tumor of Brain Stem, Pineocytoma, Choroid Plexus Carcinoma, Childhood, Spinal Cord Tumor, High Grade Glioma
What this study did

Competitive landscape

This drug's own stage for Recurrent Glioblastoma: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
NEO100: this drugStage not on recordSmall molecule—not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
DenifanstatPhase 3Small moleculeFatty acid synthase (FASN), FASNnot yet gradedNo reviewed efficacy summary in this indication
BizaxofuspPhase 2Protein / enzyme therapeuticIL-4 receptor (IL-4R)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow NEO100 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Residual, Progressive or Recurrent Grade II or III MeningiomaRecruiting
Est. primary completion 2026-12-30 · NCT05023018 · CT.gov ↗
What to watch
2027 (1)
June 2027 (1)
Phase 1Pediatric Tumor of CNS, Pediatric Tumor of Brain, Diffuse Midline Glioma, H3 K27M-Mutant, Pediatric Tumor of Brain Stem, Pineocytoma …Recruiting
Est. primary completion 2027-06 · NCT06357377 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 August 2026Topline resultPhase 2a of intranasal NEO100 in recurrent IDH1-mutant high-grade glioma met its primary endpoint
Neonc Technologies, Inc. · Source ↗